SecBot SecBot
6-K ·Filed Apr 17, 2026

GLAXF

GSK plc
NEUTRAL
Impact 3/10
Horizonimmediate Processed6mo ago SEC0001654954-26-003629
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine share buyback transaction within an ongoing program announced in February 2026. The transaction is relatively small in scale and consistent with the company's capital management strategy. Investors should monitor the cumulative effect of the buyback program on share count and EPS, but this single transaction is unlikely to materially impact the stock price.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
GLAXF ▼ -10.88% at T+60d
NEUTRAL call -10.88% · α vs SPY -17.02% · entry $29.50 → $26.29
Entry = T+0 close
Apr 17, 2026
via day close
T+1d
0.00%
call 0.00% · α +0.19%
$29.50
settled 6mo ago
T+5d
-7.76%
call -7.76% · α -8.32%
$27.21
settled 6mo ago
T+20d
-12.88%
call -12.88% · α -18.25%
$25.70
settled 6mo ago
T+60d
-10.88%
call -10.88% · α -17.02%
$26.29
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

GSK plc purchased 330,000 of its own ordinary shares on April 16, 2026, at a volume-weighted average price of 2,125.06 GBp per share, as part of its existing buyback program. The shares will be held as treasury shares.

Key Facts

  • GSK purchased 330,000 ordinary shares on April 16, 2026
  • Purchase price ranged from 2,116.00 GBp to 2,136.00 GBp per share
  • Volume-weighted average price paid was 2,125.06 GBp per share
  • Shares were purchased through BNP Paribas SA as part of an existing buyback program
  • Purchased shares will be held as treasury shares
  • Since February 17, 2026, GSK has purchased 19,526,521 ordinary shares under this program

Financial Impact

The company spent approximately £7.01 million (330,000 shares × 2,125.06 GBp) on this share repurchase

dilution

Risk Factors

  • The cautionary statement notes that forward-looking statements are subject to risks and uncertainties
  • No financial impact is indicated for this specific transaction

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-003629
Document: 0001654954-26-003629-index-headers.html0001654954-26-003629
Document: 0001654954-26-003629-index.html0001654954-26-003629
Document: 0001654954-26-003629.txt0001654954-26-003629
51 reports for GLAXF
Performance horizon
46% Hit rate @ T+5 6 of 13 directional calls Went positive at some point 7 of 13 best @ T+20▲ +9.49%Jun 9, 2026
Filters
Rows
Reports for GLAXF — sortable, filterable
TypeNow
Jun 10, 2026
19w ago
6-K
NEUTRAL ★ 1/10
$25.12 $25.25▲ +0.52%▼ −1.62%$26.12 (+3.98%)
Jun 9, 2026
20w ago
6-K
NEUTRAL ★ 1/10
$24.66 $25.50▲ +3.41%▲ +1.60%$26.12 (+5.92%)
Jun 9, 2026
20w ago
6-K
BULLISH ★ 7/10
$24.66 $25.50▲ +3.41%▲ +1.60%$26.12 (+5.92%)
Jun 1, 2026
21w ago
6-K
NEUTRAL ★ 1/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.12 (+7.71%)
Jun 1, 2026
21w ago
6-K
NEUTRAL ★ 2/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.12 (+7.71%)
May 28, 2026
21w ago
6-K
BULLISH ★ 7/10
$24.58 $24.66▲ +0.33%▲ +0.01%$26.12 (+6.27%)
May 27, 2026
21w ago
6-K
NEUTRAL ★ 1/10
$25.57 $23.94▼ −6.37%▼ −7.58%$26.12 (+2.15%)
May 26, 2026
22w ago
6-K
NEUTRAL ★ 1/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.12 (+2.43%)
May 26, 2026
22w ago
6-K
NEUTRAL ★ 2/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.12 (+2.43%)
May 22, 2026
22w ago
6-K
NEUTRAL ★ 2/10
$26.00 $24.25▼ −6.73%▼ −8.39%$26.12 (+0.46%)
Showing 10 of 51

US Market Status

Market Open — Closes in 1h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026